
Every April 1st, orphan drug manufacturer pricing resets — and most CAHs, SCHs, and RRCs miss the window entirely. In this free 60-minute webinar, Rev. Dr. Lisa Nezneski, PharmD, BCPS walks you through exactly what changed, what it means for your facility, and how to capture every dollar available to you in Q2 2026.
🗓️ Date
Wednesday, April 22nd, 2026
🕐 Time
1:30 PM Eastern
⏱️Duration
60 Minutes
💻 Platform
Live via Demio
Q2 Intelligence Briefing
Every new quarter brings a cascade of changes to your orphan drug program — pricing, formularies, manufacturer policies, and HRSA lists. Here's what reset when the calendar flipped to Q2 2026:
What You'll Discover
This is not a theory webinar. Every point maps directly to line items on your drug spend report. Bring your Q1 purchase data and get ready to find your money.
Is This For You?
340B Orphan Drug Solutions works exclusively with CAHs, SCHs, and RRCs. This is not a general 340B webinar. Every minute is specific to your entity type, your drug portfolio, and your Q2 2026 opportunity window.

We provide a safe, nurturing, and engaging environment where children feel valued and supported every day. Our staff ensures your child’s social, emotional, and educational growth.

Healthy bodies fuel healthy minds. We serve freshly prepared, balanced meals and snacks designed to meet children’s nutritional needs and encourage lifelong healthy eating habits.

Hands-on activities, creative play, and guided exploration help children learn by doing. We encourage curiosity, imagination, and problem-solving through structured and free play.

This is not a sales pitch. This is a real conversation.
Join me for a candid sit-down interview with Flaviu Simihaian, Co-Founder of Aventi Health — the only founder-owned 340B TPA in the country. Flaviu will walk us through how Aventi was built differently, who it was built for, and why small hospitals and FQHCs are at the center of everything they do.
You’ll get:
A live platform demo — see Aventi’s technology in action, built for simplicity and speed
A frank discussion on 340B TPA pricing — why most models are designed against small hospitals — and what Aventi does differently
Real talk about customer service — what it actually means to have direct access to the founders
Live Q&A — bring your toughest questions — Flaviu will answer them on air
Insight into onboarding timelines — how fast can you actually get up and running?
Your Host
Founder & CEO · 340B Orphan Drug Solutions
Lisa Nezneski is the only consultant in the country working exclusively in 340B orphan drug optimization for expansion entities. With 12 years of specialized expertise — and 40+ years in healthcare — she has reviewed facilities across the country and achieved a 100% findings rate: every single facility reviewed has had uncaptured savings. Her approach is direct, data-driven, and built entirely around the financial reality of CAH, SCH, and RRC operations.


© 2026 340B Orphan Drug Solutions. All rights reserved.